A valve procedure cut heart failure hospitalizations by over half versus monitoring in a trial
Edwards Lifesciences' PROGRESS Trial showed TAVR reduced heart failure hospitalizations by 50% vs. monitoring. TAVR also improved quality of life and safety. The trial involved 744 patients with moderate aortic stenosis. Edwards' SAPIEN 3 valve was used. Results published in NEJM.
How this was made
The 30-second read
Why it matters
The trial reports fewer heart-failure events and hospitalizations with TAVR, plus quality-of-life improvement, supporting a potential shift in treatment paradigm for at-risk moderate AS.
Market read
If investors believe the data supports earlier intervention, it can improve sentiment toward Edwards’ TAVR franchise and structural heart adoption.
What to watch
All-cause mortality at 2 years is described as similar, so investors may focus on durability, patient selection, and longer-term endpoints beyond 30 days.
Background
Moderate aortic stenosis (AS) has often been managed with passive surveillance, but the PROGRESS Trial tests proactive TAVR versus clinical surveillance in moderate AS patients with at-risk features.
Ticker impact
Edwards Lifesciences’ PROGRESS Trial reports proactive TAVR with SAPIEN 3 cut heart-failure hospitalizations to 7.4% vs 14.9% under surveillance.
Likely positive repricing as investors weigh expanded addressable use and improved outcomes versus surveillance.
The article is a primary disclosure of randomized trial outcomes tied to Edwards’ SAPIEN 3 and TAVR strategy, but it does not include regulatory approval or explicit guidance.
Market effects
Positive read-through for TAVR and structural heart peers as evidence challenges passive management of moderate AS with at-risk features.
No direct regional macro linkage; primarily US-listed medtech sentiment.
Global multicenter trial design may broaden international adoption expectations for earlier TAVR.
Counterpoint
Without regulatory label expansion or reimbursement clarity, the market may over-discount near-term revenue impact despite strong clinical signals.
Key entities
- companyEdwards Lifesciences
Sponsor/participant in the PROGRESS Trial narrative, referencing TAVR with the Edwards SAPIEN 3 platform and corporate vice president commentary.
- clinical_trialPROGRESS Trial
Randomized, multicenter trial comparing proactive transfemoral TAVR versus clinical surveillance in 744 moderate AS patients with at-risk features.
- product_platformSAPIEN 3
Edwards TAVR valve platform used in the trial arm described in the release.
